Stefania Giannelli
Overview
Explore the profile of Stefania Giannelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calabria A, Spinozzi G, Cesana D, Buscaroli E, Benedicenti F, Pais G, et al.
Nature
. 2024 Oct;
636(8041):162-171.
PMID: 39442556
Haematopoietic stem cell (HSC) gene therapy (GT) may provide lifelong reconstitution of the haematopoietic system with gene-corrected cells. However, the effects of underlying genetic diseases, replication stress and ageing on...
2.
Barzaghi F, Visconti C, Pipitone G, Bondesan S, Molli G, Giannelli S, et al.
J Infect Dis
. 2024 Jul;
231(1):e206-e212.
PMID: 38976510
Patients with severe West Nile virus and SARS-CoV-2 infections deserve accurate diagnosis of underlying diseases, determining possible anti-interferon autoantibody production, since they must receive antiviral and immunological therapies to enhance...
3.
Cesana D, Cicalese M, Calabria A, Merli P, Caruso R, Volpin M, et al.
Nat Commun
. 2024 Apr;
15(1):3662.
PMID: 38688902
Hematopoietic stem cell gene therapy (GT) using a γ-retroviral vector (γ-RV) is an effective treatment for Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency. Here, we describe a case of...
4.
Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis
Quaranta P, Basso-Ricci L, Hernandez R, Pacini G, Naldini M, Barcella M, et al.
Blood
. 2024 Mar;
143(19):1937-1952.
PMID: 38446574
In physiological conditions, few circulating hematopoietic stem/progenitor cells (cHSPCs) are present in the peripheral blood, but their contribution to human hematopoiesis remain unsolved. By integrating advanced immunophenotyping, single-cell transcriptional and...
5.
Migliavacca M, Barzaghi F, Fossati C, Rancoita P, Gabaldo M, Dionisio F, et al.
Nat Med
. 2024 Feb;
30(2):488-497.
PMID: 38355973
Adenosine deaminase (ADA) deficiency leads to severe combined immunodeficiency (SCID). Previous clinical trials showed that autologous CD34 cell gene therapy (GT) following busulfan reduced-intensity conditioning is a promising therapeutic approach...
6.
Fratini E, Migliavacca M, Barzaghi F, Fossati C, Giannelli S, Monti I, et al.
Front Immunol
. 2023 Jul;
14:1187959.
PMID: 37435083
Hemophagocytic inflammatory syndrome (HIS) is a rare form of secondary hemophagocytic lymphohistiocytosis caused by an impaired equilibrium between natural killer and cytotoxic T-cell activity, evolving in hypercytokinemia and multiorgan failure....
7.
Scala S, Ferrua F, Basso-Ricci L, Dionisio F, Omrani M, Quaranta P, et al.
Nat Commun
. 2023 May;
14(1):3068.
PMID: 37244942
Mobilized peripheral blood is increasingly used instead of bone marrow as a source of autologous hematopoietic stem/progenitor cells for ex vivo gene therapy. Here, we present an unplanned exploratory analysis...
8.
Migliavacca M, Basso Ricci L, Farinelli G, Calbi V, Tucci F, Barzaghi F, et al.
J Clin Immunol
. 2022 Aug;
42(8):1742-1747.
PMID: 35945378
X-linked chronic granulomatous disease is a rare disease caused by mutations in the CYBB gene. While more extensive knowledge is available on genetics, pathogenesis, and possible therapeutic options, mitochondrial activity...
9.
Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report
Cenciarelli S, Calbi V, Barzaghi F, Bernardo M, Oltolini C, Migliavacca M, et al.
Front Immunol
. 2020 Dec;
11:603428.
PMID: 33329599
In this work we present the case of SARS-CoV-2 infection in a 1.5-year-old boy affected by severe Wiskott-Aldrich Syndrome with previous history of autoinflammatory disease, occurring 5 months after treatment...
10.
Ferrua F, Cicalese M, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, et al.
Lancet Haematol
. 2019 Apr;
6(5):e239-e253.
PMID: 30981783
Background: Wiskott-Aldrich syndrome is a rare, life-threatening, X-linked primary immunodeficiency characterised by microthrombocytopenia, infections, eczema, autoimmunity, and malignant disease. Lentiviral vector-mediated haemopoietic stem/progenitor cell (HSPC) gene therapy is a potentially...